



*Duration of stability testing - minimum upto 8 days at ambient temp. after dispatch of specimens*

**EQAP CODE No. :** 3031

**Distribution No.:** 155-G

**Month/Year:** March/2022

**Instrument ID:** SYSMEX XP 100 A-5251

**Name & Contact No. of PT Co-ordinator:** Dr. Seema Tyagi (Prof.), Hematology, AIIMS, Delhi,  
 Tel: 9013085730 , E-Mail : accuracy2000@gmail.com

**Date of issue & status of the report:** 11-05-2022[Final].

**CBC and Retic Assessment**

| Test Parameters           | S.No. | Among Lab (Accuracy Testing) |               |                             |   |                                |         | Within Lab (Precision Testing)  |   |                                |         |
|---------------------------|-------|------------------------------|---------------|-----------------------------|---|--------------------------------|---------|---------------------------------|---|--------------------------------|---------|
|                           |       | Your Result 1                | Your Result 2 | Your Results Sum of 2 Value | Consensus result sum of 2 values (Assigned Value) | Uncertainty of Assigned Values | Z Score | Yours Results Diff. of 2 Values | Consensus Result Diff. of 2 values (Assigned Value) | Uncertainty of Assigned Values | Z Score |
| WBC x10 <sup>3</sup> /pl  | 1     | 5.2                          | 5.2           | 10.4                        | 12.4  | 0.0660                         | -1.52   | 0                               | 0.11  | 0.0120                         | -0.62   |
| RBC x10 <sup>6</sup> /pl  | 1     | 4.08                         | 4.07          | 8.15                        | 8.19  | 0.0100                         | -0.14   | 0.01                            | 0.03  | 0.0030                         | -0.54   |
| Hb g/dl                   | 1     | 12.4                         | 12.3          | 24.7                        | 24.4  | 0.0300                         | 0.45    | 0.1                             | 0.1   | 0.0080                         | 0.00    |
| HCT%                      | 1     | 33.8                         | 33.7          | 67.5                        | 71.8  | 0.1490                         | -1.19   | 0.1                             | 0.4   | 0.0280                         | -0.81   |
| MCV-fl                    | 1     | 82.8                         | 82.8          | 165.6                       | 176.3   | 0.3030                         | -1.45   | 0                               | 0.4   | 0.0290                         | -0.80   |
| MCH-Pg                    | 1     | 30.4                         | 30.2          | 60.6                        | 59.7  | 0.0880                         | 0.42    | 0.2                             | 0.2   | 0.0180                         | 0.00    |
| MCHC-g/dl                 | 1     | 36.7                         | 36.5          | 73.2                        | 67.4  | 0.1350                         | 1.54    | 0.2                             | 0.3   | 0.0240                         | -0.28   |
| Plt. x10 <sup>3</sup> /pl | 1     | 201                          | 199           | 400                         | 388   | 1.73                           | 0.30    | 2                               | 7   | 0.42                           | -0.84   |
| Retic %                   | 2     | 10                           | 8             | 18                          | 12.4  | 0.26                           | 0.83    | 2                               | 0.4   | 0.03                           | 3.60    |

**P.S . Assesment**

| YOUR REPORT    |  | CONSENSUS REPORT  |
|----------------|--|---|
| DLC%           | 3<br>Nrbc=02 , Poly=50 L=02, E=-04,<br>Mono/Promono=01 , B1=01 P.M.=01,<br>Mye=25, Meta=15, Other= | Poly: 40 - 55, Myelo: 14 - 25, Meta: 7 - 16, Blast: 2-8, Lympho: 2-6 ,<br>Promyelo: 1-5 nRBC/Eos/Baso/Mono: 0 - 5             |
| RBC Morphology | 3<br>NORMOCHROMIC NORMOCYTIC   | Predominantly: Normocytic/Normochromic; Moderate: Anisocytosis, hypochromia, Microcytosis; Mild: Macrocytosis, Poikilocytosis |
| Diagnosis      | 3<br>MYELOPROLIFERATIVE DISORDER   | Chronic Myeloid Leukemia (Chronic Phase)  |

**COMBINED DATA VALUES OF TOTAL PARTICIPANTS**

| Test parameters           | S.No. | Total participants covered in the current dist. 155--G | Total No. responded | % of Labs with Z Score 0-2   |            | % of Labs with Z Score 2-3 |            | % of Labs with Z Score >3 |            |
|---------------------------|-------|--|---------------------|--|------------|----------------------------|------------|---------------------------|------------|
|                           |       |  |                     | Among labs   | Within lab | Among labs                 | Within lab | Among labs                | Within lab |
| WBC x10 <sup>3</sup> /μl  | 1     | 264  | 262                 | 82.06  | 84.35      | 3.44                       | 3.44       | 14.5                      | 12.21      |
| RBC x10 <sup>6</sup> /μl  | 1     | 264  | 264                 | 90.15  | 88.26      | 4.92                       | 5.3        | 4.93                      | 6.44       |
| Hb g/dl                   | 1     | 264  | 264                 | 85.98  | 89.39      | 7.95                       | 4.17       | 6.07                      | 6.44       |
| HCT%                      | 1     | 264  | 262                 | 89.31  | 90.08      | 7.25                       | 4.58       | 3.44                      | 5.34       |
| MCV-fl                    | 1     | 264  | 262                 | 89.69  | 91.98      | 8.02                       | 2.29       | 2.29                      | 5.73       |
| MCH-Pg                    | 1     | 264  | 262                 | 89.69  | 90.46      | 6.11                       | 4.58       | 4.2                       | 4.96       |
| MCHC-g/dl                 | 1     | 264  | 262                 | 94.27  | 89.69      | 4.2                        | 4.58       | 1.53                      | 5.73       |
| Plt. x10 <sup>3</sup> /μl | 1     | 264  | 261                 | 87.74  | 88.51      | 7.66                       | 4.21       | 4.6                       | 7.28       |
| ReticCount%               | 2     | 264  | 264                 | 90.53  | 86.74      | 1.89                       | 5.68       | 7.58                      | 7.58       |
| PS Assessment             | 3     | 264  | 250                 | Satisfactory :85.62%, Borderline Sat. :10.22%, Unsatisfactory :4.16% |            |                            |            |                           |            |

**Comments:**

- 1). Among Lab (EQA) : **PS Diagnosis partially correct, remaining results acceptable**
- 2). Within Lab (IQA) : **RETIC result is unacceptable, may be due to random/human error.**

**Note-1:** EQA (External Quality Assurance) : Your Performance among various of participating labs in PT, to determine the accuracy of your results.

**IQA** ( Internal Quality Assurance) : Your Performance of comparison of two consecutive measurement values within your lab to test the precision of your autoanalyzer.

**Note-2:** Z score among & within lab were calculated, as per to ISO/IEC 13528:2015 standard. Z score among lab (EQA)= (Your Result Sum of two values - Consensus Result sum of two values)/(Normalised IQR)

Z score within lab (IQA)= (Your Result Difference of two values - Consensus Result difference of two values)/(Normalised IQR)

IQR = Quartile 3 - Quartile 1 of participant data, Normalised IQR = 0.7413 x IQR

**Note-3:** Z score 0 to ±2: Acceptable, Z score ±2 to ±3 :Warning Signal, Z score > ±3 : Unacceptable [As per ISO/IEC 13528:2015 standard]

**Note-4:** Z score value between "0 to ±2" are texted in green colour. Z score value between "±2 to ±3" are texted in orange colour. Z score value > ±3 are texted in red colour.

**Note-5:** Homogeneity and stability testing of PT sample were done as per ISO 13528:2015 standard. To pass homogeneity test, between sample SD (Ss) should be smaller than the check value (0.3\*SDPA). To pass the stability test, average difference in measurement values of first and last day sample ( $\bar{x}-\bar{y}$ ) should be smaller than the check value (0.3\*SDPA).

**Note-6:** ISHTM-AIIMS-EQAP does not subcontract any task of its scheme

**Note-7:** Participants are free to use methods/analyzer of their own choice.

**Note-8:** Proficiency testing (PT) samples are sent quarterly to each participant.

**Note-9:** All the necessary details regarding design and implementation of PT, are provided in the instruction sheet as well as on programme's website [www.ishtmaiimseqap.com](http://www.ishtmaiimseqap.com).

Report authorized by,



Dr. Seema Tyagi (Prof.)  
PT Co-ordinator: ISHTM-AIIMS-EQAP  
Department of Hematology, AIIMS, New Delhi

-----End Of Report-----

*CoA Required for Reti.  
CBC & PS Satisfactory*

*12/5/2022*